A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
myeloablative (19% vs. 24%, P¼0.349) and nonmyeloablative conditioning (13% vs. 9%, P¼1.000). PFS at 1 year was slightly higher for ATG1 (52.8% vs. 45.5%,P ¼ .955), while OS at 1 year was not different between the two groups (53.7% vs 55.4%,P ¼ .779). Conclusion: A small decrease in the prophylactic ATG dose (1.5mg/kg) had a significant clinical impact. An increased incidence of severe lethal acute GVHD was observed with 4.5mg/kg dosing despite a greater degree of HLA-matching. The 6.0mg/kgdoi:10.1016/j.bbmt.2012.11.490 fatcat:r5ohcsrryvbvdbcztynalfkgq4